Investor Presentation First Nine Months of 2022
74
Investor presentation First nine months of 2022
The SELECT cardiovascular outcomes trial expected to complete
in the middle of 2023
SELECT trial with 17,500 people with obesity
Semaglutide 2.4 mg
R
1:1
Placebo
Event driven
5 weeks
follow-up
Objective
Demonstrate that semaglutide 2.4 mg lowers the incidence of MACE vs
placebo
Primary endpoint
Time from randomisation to first occurrence of MACE¹
Secondary endpoints
CV death, all-cause death, 5-point MACE composite, composite HF,
composite nephropathy, glucose metabolism, other metabolic
parameters
Estimated completion
The trial is expected to complete in the middle of 2023
1 MACE includes non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death.
MACE: Major adverse cardiovascular events; HF: Heart failure; CV: Cardiovascular
Novo NordiskⓇView entire presentation